NCT01490632

A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of Baricitinib in Patients With Moderate-to-Severe Plaque Psoriasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 271 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a dose-ranging study designed to investigate the efficacy and safety of Baricitinib in the treatment of participants with moderate to severe, chronic plaque psoriasis as assessed by the Psoriasis Area and Severity Index (PASI) score and routine safety assessments.

Conditions

• Psoriasis
• Skin Diseases
• Skin Diseases, Papulosquamous

Interventions

Type	Name	Description
DRUG	Placebo	Administered orally
DRUG	Baricitinib	Administered orally

Timeline

• Start date: 2011-12-01
• Primary completion: 2012-12-01
• Completion: 2014-08-01
• First posted: 2011-12-13
• Last updated: 2019-09-27
• Results posted: 2017-07-18

Locations

35 sites across 4 countries: United States, Canada, Japan, Puerto Rico